Antimicrobial resistance in respiratory tract pathogens

References

• Enarson DA, Chretien J. Epidemiology of respiratory infectious diseases. Curr Opin. Pulm. Med 5,128–135 (1999).
   PubMedGoogle Scholar
• Sahm DE Resistance issues and community acquired respiratory infections. Clin. Cornerstone 3(Suppl.), S4—S11 (2003).
   Google Scholar
• •Good review of resistance issues in community aquired repiratory tract infections.
   Google Scholar
• Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians. J. Am. Med. Assoc. 278,901–904 (1997).
   PubMed Web of Science ®Google Scholar
• Stratton C. Mechanisms and patterns of antibiotic resistance in respiratory pathogens. J. Respir. Dis. 23(Suppl.), S15—S23 (2002).
   Google Scholar
• Dunbar LM. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance. Am. J. Med. Sci. 326,360–368 (2003).
   PubMed Web of Science ®Google Scholar
• •Another good review of resistance issues in community aquired repiratory tract infections.
   Google Scholar
• Halpern MT, Higashi MK, Bakst AW, Schmier JK. The economic impact of acute exacerbations of chronic bronchitis in the USA and Canada: a literature review. J. Manag. Care Pharm. 9,353–359 (2003).
   PubMedGoogle Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Resp. J. 22,672–688 (2003).
   PubMed Web of Science ®Google Scholar
• Ball P, Chodosh S, Grossman R, et al. Causes, epidemiology and treatment of bronchial infections. Infect. Med. 17, 186–198 (2000).
   Google Scholar
• Stratton CW Bacterial pneumonia — an overview with emphasis on pathogenesis, diagnosis and treatment. Heart Lung 15, 226–244 (1986).
   PubMedGoogle Scholar
• Fass RJ. Etiology and treatment of community acquired pneumonia in adults; an historical perspective. J. Antimicrob. Chemother. 32(Suppl. A), S17—S27 (1993).
   PubMedGoogle Scholar
• Marrie TJ. Community acquired pneumonia: epidemiology, etiology, treatment. Infect. Dis. Clin. North Am. 12, 723–740 (1998).
   PubMed Web of Science ®Google Scholar
• File TM. Community acquired pneumonia. Lancet 362,1991–2001 (2003).
   PubMed Web of Science ®Google Scholar
• Plouffe JE Importance of atypical pathogens of community acquired pneumonia. Clin.Infect. Dis. 31\(Suppl. 2), S35—S39 (2000).
   Google Scholar
• Gwaltney JM Jr. State-of-the-art acute community acquired sinusitis. Clin. Infect. Dis. 23,1209–1223 (1996).
   PubMed Web of Science ®Google Scholar
• Gwaltney JM Jr, Wiesinger BA, Patrie JT. Acute community acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history. Clin. Infect. Dis. 38, 227–233 (2004).
   PubMed Web of Science ®Google Scholar
• •Treatment of acute community aquiredbacterial sinusitis has been controversial, this article reviews these issues.
   Google Scholar
• Poole MD. A focus on acute sinusitis in adults: changes in disease management. Am. J. Med 106(Suppl. 5A), S38—S47 (1999).
   PubMedGoogle Scholar
• Anon JB, Jacobs MR, Poole MD, et al Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 130(Suppl.), S1—S45 (2004).
   PubMedGoogle Scholar
• •Recently developed guidelines for thetherapy of acute bacterial sinusitis — useful to the practicing clinician.
   Google Scholar
• MacDonald KS, Scriver SR, Skulnick M, Low DE. Community acquired pneumonia: the future of the microbiology laboratory: focused diagnosis or syndromic management? Sem. Rev. Infect. 9,180–188 (1994).
   Google Scholar
• Hindiyey M, Carroll KC. Laboratory diagnosis of atypical pneumonia. Sem. Re#iir Infect. 15,101–113 (2000).
   PubMedGoogle Scholar
• Lode H, Schaberg T, Raffenberg M, Mauch H. Diagnostic problems in lower respiratory tract infections. J Antimicrob. Chemother 32(Suppl. A), S29-537 (1993).
   PubMedGoogle Scholar
• Davies BI. Critical review of microbiological data and methods in diagnosis of lower respiratory tract infections. Monaldi Arch. Chest Dis. 49, 52–56 (1994).
   Google Scholar
• Lieberman D, Schlaaeffer F, Boldur I, et al Multiple pathogens in adult patients admitted with community acquired pneumonia: a 1 year prospective study of 346 consecutive patients. Thorax 51, 179–184 (1996).
   Google Scholar
• Grayston JT, Kuo C-C, Wang S-P, Altman J. A new Chlamydia psittaci strain, TWAR isolated in acute respiratory tract infections. N Engl J Med 315,161–168 (1986).
   PubMed Web of Science ®Google Scholar
• Friedman MG, Dvoskin B, Kahane S. Infections with the chlamydia-like microorganism Simkania negevensis, a possible emerging pathogen. Microbes Infect. 5, 1013–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Amyes SGB. Magic Bullets,Lost Horizons: the Rise and Fall ofAntibiotics. Taylor and Francis, London, UK (2001).
   Google Scholar
• Tenover FC. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin. Infect. Dis. 33\(Suppl. 3), S108-5115 (2001).
   Google Scholar
• •Excellent overview of the development andspread of bacterial resistance to antimicrobial agents, that provides the backround to these problems in community acquired respiratory tract pathogens.
   Google Scholar
• Drlica K Antibiotic resistance: can we beat the bugs? Drug Discov. Today 6,714–715 (2001).
   PubMedGoogle Scholar
• Russell AD, Chopra I. Understanding Antimicrobial Action and Resistance, Second Edition. Ellis Horwood, NY, USA (1996).
   Google Scholar
• Wise R A review of the mechanisms of action and resistance of antimicrobial agents. Can. Reipir. j 6(Suppl. A), A20—A22 (1999).
   Google Scholar
• Walsh C. Antibiotics: Actions,Origins, Resistance. ASM Press, Washington, DC, USA (2003).
   Google Scholar
• •Recent textbook on antimicrobial action and mechanisms of resistance — a good reference for these issues.
   Google Scholar
• Jacoby GA. Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin. Infect. Dis. 18,951–957 (1994).
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens — a global perspective. Semi n. Reipir. Infect. 15,195–207 (2000).
   PubMedGoogle Scholar
• Doern GV, Brown SD. Antimicrobial susceptibility among community acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Infect. 48,56–65 (2004).
   PubMed Web of Science ®Google Scholar
• •Provides the most recent susceptibility data for respiratory tract pathogensin the USA.
   Google Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community acquired pneumonia in the era of pneumococcal resistance. Arch. Intern. Med. 160, 1399–1408 (2000).
   PubMed Web of Science ®Google Scholar
• Craig WA. The hidden impact of antimicrobial resistance in respiratory tract infection. Re-evaluating current antimicrobial therapy. Resp. Med. 95(Suppl. A), S12—S19 (2001).
   Google Scholar
• Stratton CW. Antibiotic resistance: strategies for counterattack. Antimicrob. Infect. Dis. Newsletter 17, 41–47 (1998).
   Google Scholar
• Hamilton-Miller JMT. B-lactamases and their clinical significance. J. Antimicrob. Chemother. 9(Suppl. B), S11—S19 (1982).
   Google Scholar
• Stratton CW. Activity of B-lactamases against B-lactams. J. Antimicrob. Chemother. 22(Suppl. A), S23—S35 (1988).
   PubMedGoogle Scholar
• Moellering RC Jr. Meeting the challenges of B-lactamases. J. Antimicrob. Chemother. 31(Suppl. A), S1—S8 (1993).
   Google Scholar
• Livermore DM. B-lactamases in laboratory and clinical resistance. Clin. Microbial Rev. 8,557–584 (1995).
   PubMed Web of Science ®Google Scholar
• •Excellent review of ll-lactamases.
   Google Scholar
• Samaha-Kfoury JN, Arai GE Recent developments in B-lactamases and extended spectrum B-lactamases. Br. Med. J. 327,1209–1213 (2003).
   PubMed Web of Science ®Google Scholar
• •Update of the preceeding ll-lactamase review.
   Google Scholar
• Faraci WS, Pratt RF. Mechanism of inhibition of the PC1 B-lactamase of Staphylococcus aureus by cephalosporins: importance of the 3-leaving group. Biochemistry 24,903–910 (1985).
   PubMedGoogle Scholar
• Williams JD, Moosdeen F. Antibiotic resistance in Haemophilus influenzae: epidemiology, mechanisms and therapeutic possibilities. Rev. Infect. Dis. 8\(Suppl. 5), S5553—S5561 (1986).
   Google Scholar
• Reid AJ, Simpson IN, Harper PB, Amyes SG. Ampicillin resistance in Haemophilus influenzae: identification of resistance mechanisms. J. Antimicrob. Chemother. 20, 645–656 (1987).
   PubMed Web of Science ®Google Scholar
• Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin. Infect. Dis. 14,1119–1123 (1992).
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Zhanel GG, Hoban DJ. Presence of ROB-1 B-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae. J. Antimicrob. Chemother. 45,871–875 (2000).
   PubMedGoogle Scholar
• Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC. Contribution of B-lactamase and PBP amino acid substitutions of amoxicillin/davulanate resistance in B-lactamase positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J. Antimicrob. Chemother. 52,1018–1021 (2003).
   Google Scholar
• Enright MC, McKenzie H. Moraxella (Branhamella) catarrhalis — clinical and molecular aspects of a rediscovered pathogen. J. Med. Microbial 46,360–371 (1997).
   PubMed Web of Science ®Google Scholar
• Chambers HE Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J. Infect. Dis. 179\(Suppl. 2), S353—S359 (1999).
   Google Scholar
• Tomasz A. Penicillin-binding proteins in bacteria. Ann. Intern. Med. 96,502–504 (1982).
   PubMedGoogle Scholar
• •Key paper for understanding penicillin-binding proteins.
   Google Scholar
• Ghuysen JM. Serine B-lactamases and penicillin-binding proteins. Ann. Rev. Microbial 45,37–67 (1991).
   PubMed Web of Science ®Google Scholar
• Ghuysen JM. Penicillin-binding proteins and B-lactamases. Molecular structures. Trends Microbial. 2,372–380 (1994).
   PubMedGoogle Scholar
• Markiewicz Z, Tomasz A. Variation in penicillin-binding proteins of penicillin-resistant clinical isolates of pneumococci. J. Clin. Microbial 27,405–410 (1989).
   PubMed Web of Science ®Google Scholar
• Hakenbeck R, Grebe T, Zahner D, Stock JB. B-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and nonpenicillin-binding proteins. Mal Microbial 33,673–678 (1999).
   PubMed Web of Science ®Google Scholar
• Tanoue S. Clinical and laboratory evaluation of penicillin resistant Streptococcus pneumoniae in relation to the mutations of pbp la,pbp2b and pbp2x. Kurume Med. J. 48,1-8 (2001).
   Google Scholar
• Smith AM, Klugman KR Alterations in mur M, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45,2393–2396 (2001).
   PubMedGoogle Scholar
• Mendelman PM, Chaffin DO, Stull TL, Rubens CE, Mack KD, Smith AL. Characterization of non-B-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob. Agents Chemother. 26,235–244 (1984).
   Google Scholar
• Reid AJ, Simpson IN, Harper PB, Amyes SG. Ampicillin resistance in Haemophilus influenzae identification of resistance mechanisms. J. Antimicrob. Chemother 20, 645–656 (1987).
   PubMed Web of Science ®Google Scholar
• Clairoux N, Picard M, Brochu A, et al Molecular basis of the non-il-lactamase-mediated resistance to il-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrob. Agents. Chemother 36, 1504–1513 (1992).
   PubMed Web of Science ®Google Scholar
• Ubukata K, Shibasaki Y, Yamamoto K, et al Association of amino acid substitutions in penicillin-binding protein 3 with il-lactam resistance in il-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents. Chemother 45,1693–1699 (2001).
   PubMed Web of Science ®Google Scholar
• Mendelman PM, Chaffin DO, Stull TL, et al Cefuroxime treatment failure of nontypable Haemophilus influenzae meningitis associated with altered penicillin-binding proteins. J. Infect. Dis. 162,1118–1123 (1990).
   PubMed Web of Science ®Google Scholar
• Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38\(Suppl. 4), S357-5362 (2004).
   Google Scholar
• Wortmann GW, Bennett SE Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin. Infict. Dis. 29,1599–1600 (1999).
   PubMedGoogle Scholar
• Urban C, Rahman N, Zhao X, et al Fluoroquinolone-resistant Streptococcuspneumoniae associated with levofloxacin therapy. J. Infect. Dis. 184,794–798 (2001).
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM. Quinolone resistance mechanisms in pneumococci. Clin. Infict. Dis. 38\(Suppl. 4), S350—S356 (2004).
   Google Scholar
• •Important review of fluroquinoloneresistance mechanisms in pneumococci — such resistance is likely to increase in the finure.
   Google Scholar
• Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin. Infict. Dis. 38\(Suppl. 4), S322—S327 (2004).
   PubMedGoogle Scholar
• Farrell DJ, Douthwaite S, Morressey I, et al Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study. Antimicrob. Agents. Chemother 47, 1777–1783 (2003).
   PubMed Web of Science ®Google Scholar
• Borges-Walmsley MI, Walmsley AR. The structure and function of drug pumps. Trends Microbial. 9,71–79 (2001).
   PubMedGoogle Scholar
• Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64,159–204 (2004).
   PubMed Web of Science ®Google Scholar
• •Key review of efflux resistance mechanisms.
   Google Scholar
• Marshall NJ, Piddock U. Antibacterial efflux systems. Microbiologia 13,285–300 (1997).
   PubMedGoogle Scholar
• Zheleznova EE, Markham P, Edgar R, Bibi E, Neyfakh AA, Brennan RG. A structure-based mechanism for drug binding by multidrug transporters. Trends Biochem. 25,39–43 (2000).
   PubMed Web of Science ®Google Scholar
• Markham PN. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob. Agents. Chemother. 43,988–989 (1999).
   PubMed Web of Science ®Google Scholar
• BrenwaM NP, Appelbaum P, Davies T, Gill MJ. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Clin. Microbial. Infect. Dis. 9,140–143 (2003).
   PubMedGoogle Scholar
• Nishijima T, Saito Y, Aoki A, Toriya M, Toyonaga Y, Fujii R Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics. J. Antimicrob. Chemother. 43,637–643 (1999).
   PubMed Web of Science ®Google Scholar
• Thong P, Shortridge VD. The role of efflux in macrolide resistance. Drug Resist. Update 3,325–329 (2000).
   PubMedGoogle Scholar
• Sanchez L, Pan W, Vinal M, Nikaido H. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacterial 179,6855–6857 (1997).
   PubMed Web of Science ®Google Scholar
• Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 24\(Suppl. 1), S85—S88 (1997).
   Google Scholar
• Jacobs MR, Applebaum PC. Antibiotic resistant pneumococci. Rev. Med. Microbial. 6,77–93 (1995).
   Google Scholar
• Courvalin P, Carlier C. Transposable multiple antibiotic resistance in Streptococcus pneumoniae. Mal Gen. Genet. 205,291–297 (1986).
   PubMedGoogle Scholar
• Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 2,995–997 (1977).
   PubMed Web of Science ®Google Scholar
• Maskell JP, Sefton AM, Hall LM. Mechanisms of sulfonamide resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents. Chemother. 41, 2121–2126 (1997).
   PubMed Web of Science ®Google Scholar
• Huovinen P, Sundstrom L, Swedberg G, Skold O. Trimethoprim and sulfonamide resistance. Antimicrob. Agents. Chemother. 39, 279–289 (1995).
   PubMed Web of Science ®Google Scholar
• Padayachee T, Klugman KP. Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother 43,2361–2365 (1999).
   PubMed Web of Science ®Google Scholar
• McCullers JA, English BK, Novak R Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infict. Dis. 181, 369–373 (2000).
   PubMed Web of Science ®Google Scholar
• Normark BH, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin. Infect. Dis. 32,552–558 (2001).
   PubMed Web of Science ®Google Scholar
• Metlay JP, Hofmann J, Cretron MS, et al Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30,520–528 (2000).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Moroney JF, Farley MM, et al Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin. Infect. Dis. 30, 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• Harwell JI, Brown RB. The drug-resistant pneumococcus: clinical relevance, therapy and prevention. Chest 117,530–541 (2000).
   PubMed Web of Science ®Google Scholar